Comparison of Ranibizumab and Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusions in Routine Clinical Practice.

Abstract

BACKGROUND AND OBJECTIVE To determine outcomes of intravitreal ranibizumab (IVR) (Lucentis; Genentech, South San Francisco, CA) versus bevacizumab (IVB) (Avastin; Genentech, South San Francisco, CA) for treatment of macular edema (ME) secondary to retinal vein occlusion (RVO) in routine clinical practice. PATIENTS AND METHODS A retrospective study… (More)
DOI: 10.3928/23258160-20170601-04

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.